New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 04/15/2024 – 20:04
Read more about New Nova…
Novartis tender offer for MorphoSys AG commences
arcticnovartis
Thu, 04/11/2024 – 10:24
Read more about Novartis tender offer for MorphoSys AG commences
Basel, April 11, 2024 – Novartis published today the offer document for the vo…
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
arcticnovartis
Sat, 04/06/2024 – 22:19
Read more about New…
Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
arcticnovartis
Fri, 03/22/2024 – 12:34
Read more about Novartis Fabhalta® (iptacopan) receives…
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Novartis shareholders approve all resolutions proposed by the Board of Directors a…
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale ordinaire
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Les actionnaires de Novartis approuvent toutes le…
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
arcticnovartis
Tue, 03/05/2024 – 15:34
Read more about Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen…
Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA
arcticnovartis
Mon, 03/04/2024 – 07:19
Read more about Novartis presents new data on safety an…
Novartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cash
arcticnovartis
Mon, 02/05/2024 – 22:48
Read more about Novartis to strengthen oncology pipeline with agreement…
Novartis : forte performance en 2023, hausse de 10 % du chiffre d’affaires net et de 18 % du résultat opérationnel core (tcc¹), expansion de la marge. Innovation : nombreux résultats positifs de phase III
arcticnovartis
Wed, 01/31/2024 – 07:02
Read…